Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, ...
Rising cancer numbers indicate urgent need for advancements in cancer research, and stem cell research is rising to meet the challenge. < ...
Zacks.com on MSN11h
Will Iovance Biotherapeutics (IOVA) Report Negative Earnings Next Week? What You Should KnowThe market expects Iovance Biotherapeutics (IOVA) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known ...
Session: Poster Session B Abstract title:Combination immunotherapy with an albumin-binding interleukin-12 fusion protein that extends cytokine half-life, targets the tumor microenvironment, and ...
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BridgeBio Pharma (BBIO – Research Report) and ...
A Philadelphia biotechnology company founded seven years ago by two former Johnson & Johnson executives has a new leader.
PRINCETON, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company ...
Iovance Biotherapeutics Inc. (NASDAQ: IOVA) shares closed lower on Monday potentially following the company's announcement of Dan Kirby as Chief Commercial Officer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback